RCKT
ROCKET PHARMACEUTICALS, INC.
Latest Form 4:Sale$2KbyWilson Martin (General Counsel) · filed Aug 20, 2026
ROCKET PHARMACEUTICALS, INC. (RCKT) has 47 SEC Form 4 filings (55 transaction rows) in the rolling window, disclosed by 7 distinct insiders. Most recent filing: Aug 20, 2026.
The most active filer is CEO Shah Gaurav with 8 filings. Insiders have net sold $451K over the trailing 6 months.
- Industry:Biotechnology
- CEO:Gaurav D. Shah
- Employees:202
- HQ:Cranbury, NJ, US
- IPO:2015-02-18
Insider Buying
$34K
reported purchases (SEC code P)
Insider Selling
$722K
reported sales (SEC code S)
Unique Insiders
7
in the rolling window
Market Cap
$423.7M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| General Counsel | Sale | 631 | $2K | Aug 20 | SEC ↗ | |
| CEO | Sale | 2,293 | $8K | Aug 20 | SEC ↗ | |
| CEO | Sale | 2,837 | $10K | Aug 17 | SEC ↗ | |
| General Counsel | Sale | 3,493 | $12K | Aug 17 | SEC ↗ | |
Chaudhuri SarbaniFirst in 3 months | See Remarks | Sale | 4,701 | $16K | Aug 13 | SEC ↗ |
Stevens Christopher JamesFirst filing | Chief Operating Officer | Sale | 36,658 | $128K | Aug 13 | SEC ↗ |
| CEO | Sale | 55,684 | $172K | May 26 | SEC ↗ | |
| CEO | Sale | 2,409 | $7K | May 21 | SEC ↗ | |
| General Counsel | Sale | 662 | $2K | May 21 | SEC ↗ | |
| See Remarks | Sale | 384 | $1K | May 21 | SEC ↗ | |
| General Counsel | Sale | 3,361 | $12K | May 14 | SEC ↗ | |
| See Remarks | Sale | 855 | $3K | May 14 | SEC ↗ | |
| CEO | Sale | 2,728 | $10K | May 14 | SEC ↗ | |
Chaudhuri SarbaniFirst filing | See Remarks | Sale | 17,650 | $68K | May 11 | SEC ↗ |
| CEO | Sale | 5,990 | $20K | Feb 20 | SEC ↗ | |
| See Remarks | Sale | 1,157 | $4K | Feb 20 | SEC ↗ | |
| General Counsel | Sale | 1,376 | $5K | Feb 20 | SEC ↗ | |
Wilson MartinFirst in 3 months | General Counsel | Sale | 12,253 | $41K | Feb 18 | SEC ↗ |
Militello JohnFirst in 3 months | See Remarks | Sale | 3,726 | $12K | Feb 18 | SEC ↗ |
Shah GauravFirst in 3 months | CEO | Sale | 12,279 | $41K | Feb 18 | SEC ↗ |
Bjork ElisabethFirst filing | Director | Purchase | 10,000 | $34K | Jan 6 | SEC ↗ |
Schwartz Jonathan DavidFirst filing | See Remarks | Sale | 2,545 | $8K | Nov 20 | SEC ↗ |
Wilson MartinFirst filing | General Counsel | Sale | 1,646 | $5K | Nov 20 | SEC ↗ |
| See Remarks | Sale | 1,086 | $3K | Nov 20 | SEC ↗ | |
Shah GauravFirst filing | CEO | Sale | 6,276 | $19K | Nov 20 | SEC ↗ |
Militello JohnFirst filing | See Remarks | Sale | 28,918 | $115K | Oct 16 | SEC ↗ |
Related companies
ROCKET PHARMACEUTICALS, INC. is in the Healthcare sector.